New Issue: Science’s Impossible Questions. Read Now

The $1,000 Human Genome: Are We There Yet?

The race for genomes-in-a-day heats up as two companies promise this service by the end of 2012

The race to the $1,000 genome heated up today as Life Technologies, based in Carlsbad, Calif., announced that it will debut a new sequencing machine this year that will eventually be capable of decoding entire human genomes in a day for less than $1,000. The machine, called the Ion Proton, will be the successor to the Personal Genome Machine made by the company Ion Torrent, a subsidiary of Life Technologies.

Not to be outdone, Illumina, the present market leader based in San Diego, Calif., said that it will release its own genome-in-a-day contender, the HiSeq 2500, in the second half of this year. Unlike Life Technologies, which is asking customers to buy an entirely new machine, Illumina says that it will be able to upgrade existing customers’ HiSeq 2000 machines for a relatively low price.

So how will this battle of the sequencers shake out?


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Ion Torrent is positioning its new machine as a lower-cost alternative to Illumina’s $690,000 HiSeq. Scientists seem willing to believe that the Ion Proton will reach its speed goals, largely because Ion Torrent’s present model, the Personal Genome Machine, is performing well for its customers. That sets Ion Torrent apart from other companies with novel technologies that couldn’t deliver on their first-generation models, such as Pacific Biosciences of Menlo Park, Calif., which switched CEOs last week amidfinancial and legal hiccups, and the Cambridge, Mass.-based Helicos, which continues to struggle with lackluster demand for its machines.

This post at the forum SeqAnswers.com has calculated that the first sequencing chip released with the Ion Proton in mid-2012, the Proton 1, will be capable of sequencing three to six human exomes—the gene-encoding portion of the genome. Life Technologies said that the second sequencing chip released with the machine at the end of this year, the Proton II, will contain enough sensors to sequence an entire genome. Life Technologies is angling the Ion Proton to take on a clinical diagnostic-sequencing market, and plans to ask the U.S. Food and Drug Administration for clearance to use the machine as a medical device this year. So far, Illumina has captured much of the small-but-growing clinical-sequencing market.

But scientists are less convinced that the cost of sequencing a human genome with the Ion Proton will come in under $1,000, or that it would cost less to run than the HiSeq. Researchers note that at present, it would cost tens of thousands of dollars to sequence a human genome using the Personal Genome Machine. Life Technologies told me that the $1,000-human-genome estimate for the Ion Proton includes the cost of the sequencing chip and reagents for the run, but analyst Isaac Ro of Goldman Sachs reports in a research note that the Proton II chip itself will cost $1,000, so it’s unclear how exactly Life Technologies arrived at that $1,000 number.

The Ion Proton machine will cost a relatively inexpensive $149,000, so even though customers will have to pay an additional $95,000 for a server and automated sample-prep device, according to Ro, he notes that "the price point is clearly best-in-class by a wide margin."

But Illumina is offering to upgrade its present customers to the HiSeq 2500 for the fairly low cost of $50,000, so there may be little incentive for them to invest in a new Ion Proton machine, especially because they already know that Illumina’s technology is highly accurate and because the sequencing business has already been hit by the present climate of fiscal austerity. Life Technologies also appears to have annoyed some of its present customers by announcing the debut of a new device barely a year after releasing the Personal Genome Machine: "Was it really a wise move to announce a PGM-killer so early into this [machine's] life?" asks Nick Loman at the blog Pathogens: Genes and Genomes. 

Nonetheless, in the Ion Torrent platform, Life Technologies has finally found a way to give Illumina a run for its money in a way that no other company has to date, and the competition can only be a win for customers. With a slew of other sequencing technologies in various stages of development, these announcements kick off what should be another exciting year for new sequencing technologies.

This blog post is reproduced with permission from the magazine Nature. The post was first published on January 10, 2012.

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe